| Trial ID: | L6196 |
| Source ID: | NCT02198209
|
| Associated Drug: |
Liraglutide
|
| Title: |
Liraglutide Actions on the Liver: Effects on Glucose Phosphorylation
|
| Acronym: |
|
| Status: |
WITHDRAWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: Liraglutide
|
| Outcome Measures: |
Primary: Liver glucokinase activity (acute effect), We will measure liver glucokinase (GCK) activity 'in vivo' during IVGTTs with and without liraglutide administration, 12 months|Liver glucokinase activity (chronic effect), We will measure liver glucokinase (GCK) activity 'in vivo' during IVGTTs before and after 6 weeks of daily liraglutide administration, 12 months | Secondary: insulin sensitivity, We will measure SI-IVGTT (insulin sensitivity during an intravenous glucose tolerance test) as quantified by the MINMOD analysis of the IVGTT., 12 months|Acute insulin response to glucose and the disposition index, We will assess the acute insulin response to glucose (AIRg) and the disposition index (DI-MINMOD)(the ability of beta cell to compensate for changes in insulin sensitivity), 12 months
|
| Sponsor/Collaborators: |
Sponsor: Cedars-Sinai Medical Center
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
0
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE
|
| Start Date: |
2019-12
|
| Completion Date: |
2020-12
|
| Results First Posted: |
|
| Last Update Posted: |
2019-09-30
|
| Locations: |
Cedars Sinai Medical Center, Los Angeles, California, 90048, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT02198209
|
